Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
about
ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell linesKnockin of mutant PIK3CA activates multiple oncogenic pathwaysGSK-3 as potential target for therapeutic intervention in cancerDown-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment.Medullary thyroid carcinoma: targeted therapies and future directionsSpecific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growthConstitutive activation of glycogen synthase kinase-3beta correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancerInhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.Clinicopathological and biological significance of aberrant activation of glycogen synthase kinase-3 in ovarian cancerLithium inhibits carcinoid cell growth in vitroWnt/β-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells.Multi-targeted approach in the treatment of thyroid cancer.Molecular imaging of glycogen synthase kinase-3beta and casein kinase-1alpha kinases.Glycogen synthase kinase-3β is associated with the prognosis of hepatocellular carcinoma and may mediate the influence of type 2 diabetes mellitus on hepatocellular carcinoma.Signaling mechanisms in neuroendocrine tumors as targets for therapy.PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells.A preclinical and clinical study of lithium in low-grade neuroendocrine tumors.The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells.Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growthReflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis.Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney diseaseGlycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancerLithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta.Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathwaysMutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirinTumor suppressor role of notch1 and raf-1 signaling in medullary thyroid cancer cells.Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathwayTautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta.Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy.Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumorsCurrent understanding and management of medullary thyroid cancer.Follicular thyroid cancer cell growth inhibition by proteosome inhibitor MG132Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors.The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer.MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype.Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.GSK-3β protein phosphorylates and stabilizes HLXB9 protein in insulinoma cells to form a targetable mechanism of controlling insulinoma cell proliferation.Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin
P2860
Q24600930-94122FC3-4AAA-477D-A28D-76660FAFDD4AQ24657412-B2B7CD18-B1C5-44A4-8432-B05FF16605C6Q27013811-3A5C0D07-B13D-4473-B538-EEFC159297CBQ33363441-F715753B-B5B0-4F2A-AC43-3C0D9F942472Q33557376-4FF97242-7F4D-4084-8DDB-F9C252FDC6EAQ33631442-A6DE6F52-48E5-40A2-BBF9-B2CD88A9ADBFQ33655531-0D73E989-65B8-4F46-B0A7-DCD38A5CE2F3Q33804934-A8E9192C-CDAF-499B-A200-CAA87DAFF534Q33831250-5CEBFC32-CA63-4E2D-BE8C-E2BCCA463BE6Q33942103-8AF9C5F6-E0F7-4D64-BE74-DE4AA1B1D8EFQ33981498-9852A5BA-CDD6-40A3-AAE8-97ECAA0595EFQ33982413-96682C70-C184-4C49-B2CC-9F218ACFF9F7Q34069133-F73B5511-B96C-41F0-A2D6-1793DDEB3F14Q34089689-5BF3D170-DEA8-497C-A97B-AF8AE6C495D1Q34447484-1D35C399-B38F-40BE-8E96-C7D181182FEDQ34616536-FA3DDA79-4823-489C-B125-F136AA00D26CQ34658396-0EA8689C-8D5F-4221-BB00-36E9F8FA3242Q35057374-B3E5A5D3-D553-4140-A402-410A39E7CF14Q35087291-FE63D4A1-BE6C-4208-BC07-5B51372D9327Q35281886-263FF8BE-F69E-4123-B9EF-E05539C617E6Q35650633-2B623F5E-BD89-4591-96BF-5FDAF542394AQ35667570-79B90143-7824-4EDD-AD12-68CF11FD3CDAQ36019650-F3BF8E7F-D6D0-4525-ABC5-37E6CE1D38FAQ36164034-149394E0-AAF1-40F0-8760-A9BBEF2EEFAAQ36189756-C9E367AD-ABDF-48C4-885E-E54868317F9EQ36334183-162F4C7D-104D-4B80-94F4-F12CC3E4B939Q36678527-685D3E73-85C1-490A-9E37-376B2CA6FBAFQ36790872-0ABA1954-9740-4D44-A457-EE602155D4F9Q37148789-96C2650E-12BE-4BDF-98DF-50A7E62AF59EQ37161813-AFBFDDDA-8601-4403-BE3B-B777215CCA37Q37163149-EE7BD256-7D46-4F29-B462-F39B1EB52967Q37179117-4925A481-08C8-4398-A7F7-5EE45EB5B32DQ37247181-0D9C6094-50DE-4114-B425-8B642878B3DAQ37314468-6F2A2730-EA20-4338-80F8-657A2B80DF8EQ37339815-758F43EE-DEC2-4FC5-8E90-805ED0389FB5Q37350245-2EA1A973-73D3-4CB2-AF4F-A5A2AA5113B3Q37480580-4D868B79-5737-416B-8948-B7D1580FF7AFQ37481890-6E68A6CA-7084-4495-8197-2DEE96D79CB5Q37608407-06425785-8331-4146-A5C7-2C0692C24C36Q37718335-2C5C21EB-5243-4E86-A8B3-4850E739F351
P2860
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Inactivation of glycogen synth ...... edullary thyroid cancer cells.
@en
type
label
Inactivation of glycogen synth ...... edullary thyroid cancer cells.
@en
prefLabel
Inactivation of glycogen synth ...... edullary thyroid cancer cells.
@en
P2093
P1476
Inactivation of glycogen synth ...... edullary thyroid cancer cells.
@en
P2093
Abram M Vaccaro
Herbert Chen
Mary A Ndiaye
Muthusamy Kunnimalaiyaan
P304
P356
10.1158/1535-7163.MCT-06-0665
P577
2007-03-01T00:00:00Z